HC Wainwright Has Bullish Forecast for ELTX FY2026 Earnings

Elicio Therapeutics, Inc. (NASDAQ:ELTX – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for Elicio Therapeutics in a report released on Tuesday, November 10th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($1.60) for the year, up from their previous forecast of ($1.83). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Elicio Therapeutics’ current full-year earnings is ($1.71) per share. HC Wainwright also issued estimates for Elicio Therapeutics’ Q4 2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($1.12) EPS.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14.

Other research analysts have also issued reports about the company. Weiss Ratings raised Elicio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. B. Riley Financial dropped their price objective on Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. Finally, Wall Street Zen upgraded Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Get Our Latest Report on ELTX

Elicio Therapeutics Stock Performance

Shares of NASDAQ ELTX opened at $1.50 on Thursday. Elicio Therapeutics has a 12-month low of $1.25 and a 12-month high of $16.00. The stock’s fifty day simple moving average is $1.81 and its two-hundred day simple moving average is $6.42. The company has a quick ratio of 3.43, a current ratio of 3.43 and a debt-to-equity ratio of 0.38.

Institutional Investors Weigh In On Elicio Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELTX. Shah Capital Management acquired a new stake in Elicio Therapeutics in the third quarter valued at approximately $2,275,000. BlackRock Inc. purchased a new position in Elicio Therapeutics in the second quarter worth $2,995,000. Renaissance Technologies LLC grew its holdings in Elicio Therapeutics by 332.7% in the first quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock worth $1,300,000 after purchasing an additional 93,520 shares during the last quarter. Ieq Capital LLC acquired a new position in shares of Elicio Therapeutics during the third quarter worth $47,000. Finally, Marshall Wace LLP acquired a new position in shares of Elicio Therapeutics during the third quarter worth $36,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Elicio Therapeutics

(Get Free Report)

Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated. Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.

Recommended Stories

Earnings History and Estimates for Elicio Therapeutics (NASDAQ:ELTX)

Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.